PL2582683T3 - Leczenie dny moczanowej i hiperurykemii - Google Patents

Leczenie dny moczanowej i hiperurykemii

Info

Publication number
PL2582683T3
PL2582683T3 PL11796324T PL11796324T PL2582683T3 PL 2582683 T3 PL2582683 T3 PL 2582683T3 PL 11796324 T PL11796324 T PL 11796324T PL 11796324 T PL11796324 T PL 11796324T PL 2582683 T3 PL2582683 T3 PL 2582683T3
Authority
PL
Poland
Prior art keywords
hyperuricemia
gout
treatment
Prior art date
Application number
PL11796324T
Other languages
English (en)
Polish (pl)
Inventor
Jeffrey Miner
Barry D. Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2582683(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences, Inc. filed Critical Ardea Biosciences, Inc.
Publication of PL2582683T3 publication Critical patent/PL2582683T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11796324T 2010-06-15 2011-06-14 Leczenie dny moczanowej i hiperurykemii PL2582683T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
EP11796324.9A EP2582683B1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
PL2582683T3 true PL2582683T3 (pl) 2018-08-31

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11796324T PL2582683T3 (pl) 2010-06-15 2011-06-14 Leczenie dny moczanowej i hiperurykemii

Country Status (19)

Country Link
US (3) US9216179B2 (OSRAM)
EP (1) EP2582683B1 (OSRAM)
JP (1) JP5964821B2 (OSRAM)
CA (1) CA2802407C (OSRAM)
CY (1) CY1120473T1 (OSRAM)
DK (1) DK2582683T3 (OSRAM)
ES (1) ES2670700T3 (OSRAM)
HR (1) HRP20180780T1 (OSRAM)
HU (1) HUE038265T2 (OSRAM)
LT (1) LT2582683T (OSRAM)
NO (1) NO2019008I1 (OSRAM)
PL (1) PL2582683T3 (OSRAM)
PT (1) PT2582683T (OSRAM)
RS (1) RS57275B1 (OSRAM)
SI (1) SI2582683T1 (OSRAM)
SM (1) SMT201800266T1 (OSRAM)
TR (1) TR201806828T4 (OSRAM)
WO (1) WO2011159732A1 (OSRAM)
ZA (1) ZA201300055B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
UA114304C2 (uk) * 2011-11-03 2017-05-25 Ардеа Біосайєнсіс, Інк. Спосіб зниження сироваткових рівнів сечової кислоти у людини
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
US12152347B2 (en) 2018-10-26 2024-11-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
JP7440934B2 (ja) * 2019-08-21 2024-02-29 国立大学法人 東京大学 Ａｂｃｃ１１阻害剤
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914611B2 (ja) 2003-12-26 2012-04-11 キッセイ薬品工業株式会社 ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2402011B1 (en) 2004-08-25 2012-11-14 Ardea Biosciences, Inc. S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
EP2120956A4 (en) 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
EA201270666A1 (ru) 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
JP2012502050A (ja) 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
US9402827B2 (en) * 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
EP2627331A4 (en) * 2010-10-15 2014-03-12 Ardea Biosciences Inc METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
MX2013007505A (es) 2010-12-30 2013-08-01 Ardea Biosciences Inc Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1 -il)-4h-1,2,4-triazol-3-iltio)acetico y usos de los mismos.
US20140171424A1 (en) 2011-05-24 2014-06-19 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Also Published As

Publication number Publication date
US20160143889A1 (en) 2016-05-26
RS57275B1 (sr) 2018-08-31
ES2670700T3 (es) 2018-05-31
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
DK2582683T3 (en) 2018-06-06
WO2011159732A1 (en) 2011-12-22
CY1120473T1 (el) 2019-07-10
SMT201800266T1 (it) 2018-07-17
NO2019008I1 (no) 2019-02-19
TR201806828T4 (tr) 2018-06-21
EP2582683B1 (en) 2018-03-21
ZA201300055B (en) 2018-05-30
US9216179B2 (en) 2015-12-22
JP5964821B2 (ja) 2016-08-03
PT2582683T (pt) 2018-05-25
CA2802407A1 (en) 2011-12-22
EP2582683A1 (en) 2013-04-24
JP2013528650A (ja) 2013-07-11
US20190015392A1 (en) 2019-01-17
HRP20180780T1 (hr) 2018-07-13
EP2582683A4 (en) 2014-04-30
SI2582683T1 (en) 2018-07-31
CA2802407C (en) 2018-01-23
HUE038265T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
PL2582683T3 (pl) Leczenie dny moczanowej i hiperurykemii
IL248530A0 (en) Biomarkers and treatment methods
PL2552959T3 (pl) Przeciwciała przeciwko MUC16 i metody stosowania
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
PL2640375T3 (pl) Sposób leczenia nefropatii pokontrastowej
PL2503892T3 (pl) Zastosowanie organizmu grzybowego pythium oligandrum
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
EP2547292A4 (en) INTERVERTEBRAL IMPLANTS AND SYSTEMS AND METHODS FOR IMPLANTATION OF A GRAFT
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
SG10201503168VA (en) Inhibitors of arginase and their therapeutic applications
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
EP2590982A4 (en) PROTEIN KINASE INHIBITOR AND TREATMENT PROCEDURE THEREWITH
BR112013009496A2 (pt) artigos absorventes e métodos de fabricação dos mesmos
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
ZA201207973B (en) Treatment of gout
IL257069B (en) Inhibitors of apoptosis and uses thereof
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
EP2433996A4 (en) LIQUID COMPOSITION AND ENDOSCOPE
DK2642992T3 (da) Forbindelser og anvendelse deraf
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
SMT201600059B (it) Trattamento di infezioni da streptococco
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
PL2632475T3 (pl) Kompozycje do leczenia wrzodów peryferyjnych o zróżnicowanym pochodzeniu
EP2627391A4 (en) HYDROPHOBIC CATHETER AND COMPOSITION